T-cell masthead image

Legal Notice

PLEASE READ THIS AGREEMENT CAREFULLY BEFORE ACCESSING THIS WEBSITE. THIS IS A LEGALLY BINDING AGREEMENT BETWEEN YOU AS A USER OF THE SOLIGENIX.COM SITE (“USER” OR “YOU”) AND SOLIGENIX, INC. (“SOLIGENIX” OR “WE”). BY ACCESSING OR USING THE SITE, YOU AGREE THAT YOU HAVE READ, UNDERSTAND AND AGREE TO BE BOUND BY THE TERMS AND CONDITIONS AND PRIVACY POLICY BELOW COLLECTIVELY, THE “AGREEMENT”).

IF YOU HAVE NOT READ THIS AGREEMENT, DO NOT UNDERSTAND OR DO NOT WISH TO BE BOUND BY THESE TERMS AND CONDITIONS, OR ARE NOT ABLE TO CONSENT TO BE BOUND BY THIS AGREEMENT (E.G., IF YOU ARE NOT OLD ENOUGH TO ENTER INTO A BINDING LEGAL CONTRACT), YOU MAY NOT ACCESS OR USE THIS SITE.

Scope and Acceptance:

Anyone who accesses or uses the site is a user. This Agreement sets forth your rights and obligations as a user with respect to your access to and use of the site and use of any and all information of any kind arising from access to, or use of, the site, including, without limitation, any text, graphics, photos, audio, video, or other content.

If you are accessing or using the site on behalf of any business, organization, or other entity of any kind, you represent and warrant that you are authorized (a) to accept these terms on its behalf and (b) to bind such business, organization, or entity to this Agreement.

The site is not intended or authorized for use by persons under the age of thirteen (13). By using the site, you represent and warrant that you are thirteen (13) years of age or older and that you agree to and agree to abide by all of the terms and conditions of this Agreement. If Soligenix believes that you are under the age of thirteen (13) or that you are not old enough to consent to and be legally bound by this Agreement, we may, at any time, in our sole discretion, and with or without notice: (i) terminate your access to or use of the site (or any portion, aspect, or feature thereof), or (ii) delete any information that you have submitted through the site.

WE RESERVE THE RIGHT, AT OUR SOLE DISCRETION, TO MODIFY THIS AGREEMENT (INCLUDING THE PRIVACY POLICY) FROM TIME TO TIME, WITHOUT PRIOR NOTICE. ANY CHANGES TO THIS AGREEMENT WILL BE EFFECTIVE IMMEDIATELY UPON POSTING OF THE REVISED AGREEMENT ON THE SITE, AND YOU WAIVE ANY RIGHT YOU MAY HAVE TO RECEIVE SPECIFIC NOTICE OF SUCH CHANGES. IT IS YOUR RESPONSIBILITY TO CHECK THIS AGREEMENT PERIODICALLY FOR CHANGES. YOUR CONTINUED USE OF THE SITE FOLLOWING THE POSTING OF CHANGES WILL MEAN THAT YOU ACCEPT AND AGREE TO THE CHANGES. YOU AGREE THAT YOUR SOLE AND EXCLUSIVE REMEDY WITH RESPECT TO ANY CHANGES TO THIS AGREEMENT IS TO DISCONTINUE USE OF THE SITE.

Soligenix is working hard to ensure that the information provided on this site is accurate and up-to-date but due to the risk that the information may be compromised by software or procedural errors, Soligenix does not guarantee the accuracy or completeness of the information provided on this site. Soligenix reserves the right to make changes to the content of this site from time to time without notice or obligation.

Permission to Browse Site and Limited Permission to Make Copies:

You may browse this site for information and may print copies of its contents for your own personal and non-commercial use, provided that all hard copies retain all copyright, proprietary and other applicable notices contained in such materials. Written permission is required, however, for any other use, including if you want to incorporate the contents into you own site or written materials, create “derivative works” or revise the site contents. In addition, you may not “mirror” the contents of this site or use any automated means to access or use the site, including scripts, bots, scrapers, data miners, or similar software, without Soligenix’s written permission. To seek permission, please e-mail us here.

You agree not to use this site or any aspect or feature thereof for any unlawful purpose or in any way that might harm, damage, or disparage any other party.

Any rights not expressly granted herein are reserved.

Remember: Although it may be easy to copy in cyberspace, this does not mean it is legal to do so.

Photo Credits: PhotoDisc, The Image Works, meister.NET and Soligenix, Inc.

Trademarks: Soligenix®, orBec®, OrbeShield®, RiVax®, ThermoVax®, and VeloThrax® are registered trademarks of Soligenix, Inc. Registrations exist in the United States and various countries throughout the world. Humira® is a trademark of AbbVie Biotechnology Ltd. Remicade® is a trademark of Janssen Biotech, Inc. For more complete information regarding the status of a particular trademark in a particular country, please contact Soligenix.

Copyrights: Copyright in the pages and in the screens displaying the pages, and in the information and material therein and in their arrangement, is owned by the Soligenix, Inc. unless otherwise indicated. Some contents of this site may be registered with the U.S. Copyright Office. Please familiarize yourself with U.S. and International Copyright laws before using any material.

Links to Third Party Websites:

The site may also contain references or links to third-party websites, services or other properties, not maintained or controlled by Soligenix. These references and links are provided solely as a convenience, and access or use of any such third party site shall be at your own risk. Please understand that when you access another website through this one, Soligenix can accept no responsibility for your experience with the site. In addition, any reference or  link to a non-Soligenix site does not mean that Soligenix endorses or recommends that site or its contents. Soligenix expressly disclaims any responsibility for the content of any third-party websites linked to our site. We encourage you to review the third party agreements of any third party website you choose to access, as their agreements may differ from ours.

Stock Information: The information provided in the Investor Relations section of this site is provided through a hypertext link to a third party website. (See above for important information about links to third party websites.) Under no circumstances will Soligenix be liable for any loss or direct, indirect, incidental, special or consequential damages caused by reliance on this information or for the inherent risks of the stock market.

Communications with Soligenix: Any communications or material transmitted to Soligenix will be treated as non-confidential and non-proprietary unless otherwise noted. Soligenix shall be free to reproduce, use, disclose and distribute these communications to third parties without restriction. Soligenix shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing, and marketing products incorporating such information.

No Warranties; Limitations of Liability: Soligenix assumes no responsibility for errors or omissions on this website. ACCESS TO THIS SITE IS PROVIDED “AS IS” AND “AS AVAILABLE” WITHOUT REPRESENTATION OR WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT. SOLIGENIX ALSO MAKES NO REPRESENTATIONS OR WARRANTIES THAT THE SITE WILL MEET YOUR REQUIREMENTS, OR THAT YOUR ACCESS TO AND USE OF THE SITE WILL BE UNINTERRUPTED OR ERROR-FREE, FREE OF VIRUSES, MALICIOUS CODE, OR OTHER HARMFUL COMPONENTS, OR OTHERWISE WILL BE SECURE. SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF CERTAIN WARRANTIES. ACCORDINGLY, SOME OF THE ABOVE EXCLUSIONS MAY NOT APPLY TO YOU.

TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL SOLIGENIX OR ANY OF ITS AFFILIATES, PARTNERS, OFFICERS, EMPLOYEES, AGENTS, CONTRACTORS, SUCCESSORS OR ASSIGNEES BE LIABLE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION LOST REVENUES OR LOST PROFITS, WHICH MAY RESULT FROM OR IN CONNECTION WITH THE ACCESS TO OR USE OF THIS SITE, EVEN IF SOLIGENIX HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THESE LIMITATIONS SHALL APPLY NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.

If, despite the foregoing limitations of liability, a court or other tribunal of competent jurisdiction decides to award monetary damages to you for any claim or cause of action arising with respect to the Agreement or the website, the amount of monetary damages for such claim or cause of action shall not exceed one hundred U.S. dollars ($100).

Privacy:

Please see our Privacy Policy for a detailed description of how we collect, use, and disclose information about our website users. Anyone using this website acknowledges that Soligenix may monitor the website contents as needed to comply with the law, to protect Soligenix and visitors to this website and to ensure that the website is being operated properly.

Policy on Financial Conflicts of Interest (FCOI) in Public Health Service (PHS) Funded Research

This Policy implements Financial Conflicts of Interest (FCOI) disclosure requirements found in 42 CFR Part 50 and 45 CFR Part 94 which are applicable to Research funded by the U.S. Public Health Service. This regulation does not apply to Phase I Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) program applications or awards. As a condition for receiving PHS funding, these regulations require Soligenix to maintain an appropriate written policy on financial conflict of interest disclosure. These requirements are applicable to all Research projects for which Soligenix submits a proposal to or receives Research funding from PHS, except for Phase I SBIR or STTR Research projects, as noted above. Each Investigator, as defined in the Policy, that is planning to participate in, or is participating in such Research, must follow this process and complete the required training. Subcontractors/consultants who perform services within the definition of an Investigator must maintain a policy that complies with the aforementioned regulatory requirements or comply with this Policy. Questions regarding this Policy should be directed to Soligenix’s Institutional Official.

Consistent with these requirements, Soligenix’s Policy, Soligenix FCOI Disclosure Form and required FCOI Disclosures are available. The FCOI Disclosure information was initially approved on August 24, 2012 and is subject to updates at least annually as well as within 60 days of Soligenix’s identification of a new Financial Conflict of Interest.

Forward-Looking Statements

This website may contain forward-looking statements that reflect Soligenix, Inc.’s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as “anticipates,” “estimates,” “believes,” “hopes,” “intends,” “plans,” “expects,” “goal,” “may,” “suggest,” “will,” “potential,” or similar expressions, are forward-looking statements.

These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to timing or success of the Phase 3 clinical trial of SGX942 (dusquetide) as a treatment for oral mucositis in patients with head and neck cancer receiving chemoradiation therapy or the Phase 3 clinical trial of SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma. There also can be no assurance as to timing or success of the preclinical/clinical trials of RiVax®, that RiVax® will be approved for the PRV program or the amount for which a PRV for RiVax® can be sold. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix’s reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

About Soligenix, Inc.

Located in Princeton, New Jersey, Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Soligenix’s BioTherapeutics business segment is developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn’s disease (SGX203) and acute radiation enteritis (SGX201).

Our Vaccines/BioDefense business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease. The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).